Background Prostate cancer is one of the most common malignant tumors and poses a substantial threat to human health. PSA or enhanced MRI is widely used in prostate cancer screening or diagnosis. However, false-positive PSA or enhanced MRI results can lead to misdiagnosis and incorrect puncture biopsy, while false-negative PSA or enhanced MRI results can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, economical and non-invasive diagnostic methods to reduce the PSA or enhanced MRI false-negative and false-positive rates. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in prostate cancer. Patients and methods The study finally included 464 subjects with positive PSA test (prostate cancer group, n=292; BPH group, n=172). Remaining serum samples from the subjects were collected and tested with YiDiXie™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D were evaluated respectively. Results The sensitivity of YiDiXie™-SS was 100% (95% CI: 98.7% - 100%) and its specificity was 60.5% (95% CI: 53.0% - 67.5%). This means that YiDiXie™-SS has an extremely high sensitivity and relatively high specificity in prostate tumors.YiDiXie™-HS has a sensitivity of 93.8% (95% CI: 90.5% - 96.1%) and a specificity of 86.0% (95% CI: 80.1% - 90.4%). This means that YiDiXie™ -HS has high sensitivity and specificity in prostate tumors.YiDiXie™-D has a sensitivity of 80.8% (95% CI: 75.9% - 84.9%) and a specificity of 93.0% (95% CI: 88.2% - 96.0%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in prostate tumors.YiDiXie™-SS had a sensitivity of 100% (95% CI: 98.6% - 100%), 100% (95% CI: 97.6% - 100%) and specificity of 57.7% (95% CI: 49.8% - 65.2%), 59.6% (95% CI. 49.5% - 68.9%). This means that the application of YiDiXie™-SS reduced the false positive rate of PSA and enhanced MRI by 57.7% (95% CI: 49.8% - 65.2%), 59.6% (95% CI: 49.5% - 68.9%), respectively, with essentially no increase in the underdiagnosis of malignant tumors.YiDiXie™-HS had a sensitivity of 92.3% (95% CI: 66.7% - 99.6%), 90.2% (95% CI: 79.0% - 95.7%), and specificity of 81.3% (95% CI: 57.0% - 93.4%), 83.3% (95% CI : 55.2% - 97.0%),respectively. This means that the application of YiDiXie™-HS reduced the false-negative rate of PSA and enhanced MRI by 92.3% (95% CI: 66.7% - 99.6%), 90.2% (95% CI: 79.0% - 95.7%), respectively.The sensitivity of YiDiXie™-D in PSA and enhanced MRI positive patients was 81.0% (95% CI: 76.0% - 85.2%), 83.6% (95% CI: 77.1% - 88.6%), respectively, and its specificity was 92.9% (95% CI: 87.8% - 96.0%), 92.6% (95% CI : 85.4% - 96.3%), respectively. This means that YiDiXie™-D reduced PSA and enhanced MRI false positive rates by 92.9% (95% CI: 87.8% - 96.0%), 92.6% (95% CI: 85.4% - 96.3%), respectively.YiDiXie™-D had a sensitivity of 76.9% (95% CI: 49.7% - 91.8%) and 76.5% (95% CI: 63.2% - 86.0%) in PSA- and enhanced MRI-negative patients, respectively, and its specificity was 93.8% (95% CI: 71.7% - 99.7%) and 83.3% (95% CI : 55.2% - 97.0%), respectively. This means that YiDiXie™-D reduced PSA and enhanced MRI false-negative rates by 76.9% (95% CI: 49.7% - 91.8%) and 76.5% (95% CI: 63.2% - 86.0%), respectively, while maintaining a high specificity.. Conclusion YiDiXie™-SS has very high sensitivity and relatively high specificity in prostate tumors.YiDiXie™-HS has high sensitivity and high specificity in prostate tumors.YiDiXie ™ -D has relatively high sensitivity and very high specificity in prostate tumors. YiDiXie ™-SS significantly reduces the rate of PSA or enhanced MRI false positives with essentially no increase in delayed treatment for prostate cancer.YiDiXie™-HS significantly reduces the rate of PSA or enhanced MRI false negatives.YiDiXie™-D significantly reduces the rate of PSA or enhanced MRI false positives or significantly reduces the rate of false negatives thereof while maintaining a high level of specificity. YiDiXie™ tests can play an important role in prostate cancer, and are expected to solve the problem of “high false-positive rate” and “high false-negative rate” of PSA or enhanced MRI. Clinical trial number ChiCTR2200066840.
Background Liver cancer is one of the cancers that consistently ranks among the top five cancers in terms of incidence and mortality in many countries. However, false-positive results on enhanced CT can lead to misdiagnosis and incorrect surgery or treatment, while false-negative results on enhanced CT can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive rate of ultrasound and the false-negative and false-positive rates of enhanced CT for liver tumors. The purpose of this study is to evaluate the diagnostic value of YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D in liver tumors. Patients and methods This study finally included 217 subjects (the malignant group, n=185; the benign group, n=32). Remaining serum samples from the subjects were collected and tested using the YiDiXie™ all-cancer detection kit, which was applied to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively. Results The sensitivity of YiDiXie™-SS was 98.9% (96.1% - 99.8%) and its specificity was 68.8% (51.4% - 82.0%). This means that YiDiXie™-SS has very high sensitivity and high specificity in liver tumors.YiDiXie™-HS has a sensitivity of 88.1% (82.7% - 92.0%) and its specificity is 84.4% (68.2% - 93.1%). This means that YiDiXie™-HS has high sensitivity and high specificity in liver tumors.YiDiXie™-D has a sensitivity of 72.4% (65.6% - 78.4%) and its specificity is 93.8% (79.9% - 98.9%). This means that YiDiXie™-D has high sensitivity and very high specificity in liver tumors.YiDiXie™-SS has a sensitivity of 99.2% (95.8% - 100%) and a specificity of 66.7% (39.1% - 86.2%) in patients with positive enhanced CT. This means that the application of YiDiXie™-SS reduces the false-positive rate of enhanced CT by 66.7% (39.1% - 86.2%) with essentially no increase in the leakage of malignant tumors.YiDiXie™-HS has a sensitivity of 89.1% (95% CI: 78.2% - 94.9%) in patients with a negative enhanced CT, and its specificity is 85.0% (64.0% - 94.8%). This means that YiDiXie™-HS reduces the false-negative rate of enhanced CT by 85.0% (64.0% - 94.8%). YiDiXie™-D has a sensitivity of 73.1% (64.9% - 80.0%) and a specificity of 91.7% (64.6% - 99.6%) in patients with positive enhanced CT. This means that YiDiXie™-D reduces the false-positive rate of enhanced CT by 91.7% (64.6% - 99.6%). YiDiXie™-D has a sensitivity of 70.9% (95% CI: 57.9% - 81.2%) and a specificity of 95.0% (95% CI: 76.4% - 99.7%) in patients with negative enhanced CT. This means that YiDiXie ™ -D reduces the false-negative rate of enhanced CT by 70.9% (95% CI: 57.9% - 81.2%) while maintaining high specificity. Conclusion YiDiXie™-SS has very high sensitivity and high specificity in liver tumors. YiDiXie™-HS has high sensitivity and high specificity in liver tumors. YiDiXie™-D has high sensitivity and very high specificity in liver tumors. YiDiXie™-SS significantly reduces the false positive rate of liver-enhanced CT with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS significantly reduces the false-negative rate of enhanced CT. YiDiXie™-D can significantly reduce the false-positive rate of enhanced CT or significantly reduce the false-negative rate of enhanced CT while maintaining a high specificity. The YiDiXie™ test has significant diagnostic value in liver tumors, and is expected to solve the problems of “high false-positive rate” and “high false-negative rate” of enhanced CT in liver tumors. Clinical trial number ChiCTR2200066840.
Abstract Prostate cancer is the fifth leading cause of male cancer mortality and poses a serious threat to men's health worldwide. PSA testing is widely used in prostate cancer screening, but its high false-positive rate leads to unnecessarily high subsequent testing costs, mental anguish and potential physical harm to patients. Therefore, there is an urgent need to develop a convenient, cost-effective and non-invasive diagnostic method to assist in reducing the false-positive rate of PSA screening. The aim of this study was to evaluate the diagnostic value of serum MicroRNA expression in patients with prostate cancer. We selected 10 miRNAs in the literature that were associated with prostate cancer. Afterwards, we measured the expression levels of these miRNAs in serum of 112 prostate cancer patients and healthy controls through a training phase and a validation phase. By plotting receiver operating characteristic curve, the miRNAs with the highest diagnosis value were chosen. Then, a set of miRNAs with the top diagnostic value was identified using stepwise logistic regression. The findings showed that 5 kinds of miRNAs (let-7b-5p, miR-15a-5p, miR-133a-3p, miR-15b-5p, miR-144-3p) were abnormally expressed in the serum of prostate cancer patients. The diagnostic panel constructed with these 3 miRNAs including let-7b-5p, miR-15a-5p miR-15b-5p and which have high specificity and sensitivity in detecting prostate cancer (area under the curve (AUC) = 0.899). Our study illustrates the potential of a three-microRNA panel in the diagnosis of prostate cancer, which can help in the early detection of prostate cancer and may even assist in reducing the false-positive rate of PSA screening.
Background Gastric cancer poses a severe risk to public health and has a substantial financial impact. Tumor markers such as CEA, CA125, CA19-9, and others, as well as the fecal occult blood test (FOBT), are frequently utilized for gastric cancer screening and initial diagnosis. However, false-positive results of FOBT, CEA, CA125, and CA19-9 can lead to misdiagnosis and erroneous gastroscopy, while their false-negative results can lead to missed diagnosis and delayed treatment. Finding practical, affordable, and non-invasive diagnostic techniques is crucial to lowering the false-positive and false-negative rates of FOBT and other markers. The aim of this study was to evaluate the diagnostic value of YiDiXie ™-SS, YiDiXie™-HS and YiDiXie™-D in gastric cancer. Patients and methods This study included 602 subjects (Malignant group, n=222; Benign group, n=380 cases). The remaining serum samples of the subjects were collected and the sensitivity and specificity of the YiDiXie™-SS, YiDiXie™ -HS and YiDiXie™-D were evaluated using the YiDiXie™ all-cancer detection kit. Results The sensitivity of YiDiXie™-SS was 99.5% (95% CI: 97.5% - 100%) and its specificity was 64.5% (95% CI: 59.5% - 69.1%). This means that YiDiXie™-SS has an extremely high sensitivity and relatively high specificity in gastric tumors.YiDiXie™-HS has a sensitivity of 96.8% (95% CI: 93.6% - 98.5%) and a specificity of 89.5% (95% CI: 86.0% - 92.2%). This means that YiDiXie™ -HS has high sensitivity and high specificity in gastric tumors. The sensitivity of YiDiXie™-D was 83.3% (95% CI: 77.9% - 87.7%) and its specificity was 95.5% (95% CI: 93.0% - 97.2%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in gastric tumors. YiDiXie™-SS significantly reduced the false-positive rates of FOBT, CEA, CA125, and CA19-9 with essentially no increase in malignancy leakage.YiDiXie™-HS substantially reduced the false-negative rates of FOBT, CEA, CA125, and CA19-9. YiDiXie™-D significantly reduces the false positive rate of FOBT, CEA, CA125, CA19-9. YiDiXie™-D significantly reduces the false negative rate of FOBT, CEA, CA125, CA19-9 while maintaining a high level of specificity. Conclusion YiDiXie™-SS has very high sensitivity and relatively high specificity in gastric tumors.YiDiXie™-HS has high sensitivity and high specificity in gastric tumors.YiDiXie ™ -D has relatively high sensitivity and very high specificity in gastric tumors. YiDiXie ™ -SS significantly reduces the false-positive rates of FOBT, CEA, CA125, and CA19-9 with essentially no increase in delayed treatment of gastric cancer.YiDiXie™-HS significantly reduces the false-negative rates of FOBT, CEA, CA125, and CA19-9.YiDiXie™-D can significantly reduce the false-positive rate of FOBT, CEA, CA125 and CA19-9, or significantly reduce the false-negative rate of FOBT, CEA, CA125 and CA19-9 while maintaining a high degree of specificity. YiDiXie™ test has an important diagnostic value in gastric cancer, and is expected to solve the problems of “high false positive rate” and “high false negative rate” of FOBT, CEA, CA125 and CA19-9.
Colorectal cancer (CRC) is a common malignancy of the gastrointestinal tract, often accompanied by poor prognosis and high incidence and mortality. p21 activated kinases (PAKs) have been used as therapeutic targets because of their central role in many oncogenic signaling networks. By exploring tumor databases, we found that PAK1 overexpression is associated with poor prognosis in colorectal cancer, and therefore, PAK1-targeted inhibition is a new potential therapeutic strategy for colorectal cancer. We identified that Balanol (compound 6, DB04098) can effectively target PAK1 by high-throughput virtual screening. In vitro, compound 6 exhibited favorable PAK1 inhibition with potent anti-proliferative and anti-migration activity in SW480 cells. Additionally, we also found that compound 6 induced apoptosis and cytoprotective autophagy in SW480 cells. Together, these results indicate that compound 6 is a potential novel PAK1 inhibitor, which would be utilized as a candidate compound for future CRC treatment.
Background Uroepithelial carcinoma is a serious threat to human health and causes heavy economic burden. Enhanced CT is widely used in screening or preliminary diagnosis of uroepithelial tumors. However, false-positive results on enhanced CT can lead to misdiagnosis and incorrect endoscopy, while false-negative results on enhanced CT can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of enhanced CT in uroepithelial tumors. The aim of this study was to evaluate the diagnostic value of YiDiXie ™ -SS, YiDiXie ™ -HS and YiDiXie ™ -D in uroepithelial carcinoma. Patients and methods 319 subjects (malignant group, n=240; benign group, n=79) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS and YiDiXie™-HS. Results The sensitivity of YiDiXie™ SS was 95.8% (95% CI: 92.5% - 97.7%) and its specificity was 64.6% (95% CI: 53.6% - 74.2%). This means that YiDiXie ™ -SS has an extremely high sensitivity and relatively high specificity in urothelial tumors.YiDiXie™-HS has a sensitivity of 85.8% (95% CI: 80.9% - 89.7%) and a specificity of 84.8% (95% CI: 75.3% - 91.1%). This means that YiDiXie™-HS has high sensitivity and specificity in urothelial tumors.YiDiXie™-D has a sensitivity of 73.3% (95% CI: 67.4% - 78.5%) and a specificity of 92.4% (95% CI: 84.4% - 96.5%). This means that YiDiXie ™ -D has relatively high sensitivity and very high specificity in urothelial tumors. The sensitivity of YiDiXie™-SS in enhanced CT-positive patients was 96.3% (95% CI: 96.3% - 98.3%)and its specificity was 64.3% (95% CI: 38.8% - 83.7%). This means that the application of YiDiXie™-SS reduces the false-positive rate of urological enhanced CT by 64.3% (95% CI: 38.8% - 83.7%) with essentially no increase in malignancy leakage. The sensitivity of YiDiXie™-HS in enhanced CT-negative patients was 85.5% (95% CI: 75.9% - 91.7%)and its specificity was 84.6% (95% CI: 73.9% - 91.4%). This means that the application of YiDiXie™-HS reduces the false-negative rate of urological enhanced CT by 85.5% (95% CI: 75.9% - 91.7%).YiDiXie™-D had a sensitivity of 75.6% (95% CI: 68.5% - 81.5%) and a specificity of 92.9% (95% CI: 68.5% - 99.6%) in patients with enhanced CT positivity. This means that YiDiXie ™ -D reduced the rate of false positives in enhanced CT by 92.9% (95% CI: 87.8% - 96.0%). YiDiXie ™ -D has a sensitivity of 68.4% (95% CI: 57.3% - 77.8%) and a specificity of 92.3% (95% CI: 83.2% - 96.7%) in patients with enhanced CT negativity. This means that YiDiXie™-D reduces the false-negative rate of enhanced CT by 68.4% (95% CI: 57.3% - 77.8%) while maintaining high specificity. Conclusion YiDiXie™-SS has extremely high sensitivity and relatively high specificity in urological tumors. YiDiXie™-HS has high sensitivity and high specificity in urological tumors. YiDiXie™-D has relatively high sensitivity and extremely high specificity in urological tumors. YiDiXie ™ -SS dramatically reduces urological enhanced CT false-positive rates with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS substantially reduces urological enhanced CT false-negative rates.YiDiXie ™ -D substantially reduces urological enhanced CT false-positive rates, or significantly reduces urological enhanced CT false-negative rates while maintaining high specificity. YiDiXie™ tests has important diagnostic value in uroepithelial cancer, and is expected to solve the problems of “high false positive rate” and “high false negative rate” of urological enhanced CT. Clinical trial number ChiCTR2200066840.
Background Colorectal cancer poses a severe risk to public health and has a substantial financial impact. Tumor markers such as CEA, CA125, CA19-9, and others, as well as the fecal occult blood test (FOBT), are frequently utilized for colorectal cancer screening and initial diagnosis. However, false-positive results of FOBT, CEA, CA125, and CA19-9 can lead to misdiagnosis and wrong colorectaloscopy, while their false-negative results can lead to missed diagnosis and delayed treatment. Finding practical, affordable, and non-invasive diagnostic techniques is crucial to lowering the false-positive and false-negative rates of FOBT and other indicators. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in colorectal cancer. Patients and methods This study eventually included 916 participants (602 in the malignant group and 314 in the benign group). Serum samples from individuals were obtained and examined using the YiDiXie™ all-cancer detection kit to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively. Results The sensitivity of YiDiXie™-SS was 99.0% (95% CI: 97.8% - 99.5%) and its specificity was 63.1% (95% CI: 57.6% - 68.2%). This means that YiDiXie ™ -SS has an extremely high sensitivity and relatively high specificity in colorectal tumors.YiDiXie™-HS has a sensitivity of 93.7% (95% CI: 91.5% - 95.4%) and a specificity of 86.3% (95% CI: 82.1% - 89.7%). This means that YiDiXie™-HS has high sensitivity and specificity in colorectal tumors.YiDiXie™-D has a sensitivity of 82.6% (95% CI: 79.3% - 85.4%) and a specificity of 93.9% (95% CI: 90.7% - 96.1%). This means that YiDiXie ™ -D has relatively high sensitivity and very high specificity in colorectal tumors. YiDiXie ™-SS significantly reduced the false-positive rates of FOBT, CEA, CA125, and CA19-9 with essentially no increase in malignancy leakage. YiDiXie™-HS substantially reduced the false-negative rates of FOBT, CEA, CA125, and CA19-9. YiDiXie™-D significantly reduces the false positive rate of FOBT, CEA, CA125, CA19-9. YiDiXie™-D significantly reduces the false negative rate of FOBT, CEA, CA125, CA19-9 while maintaining a high level of specificity. Conclusion YiDiXie™-SS has very high sensitivity and relatively high specificity in colorectal tumors.YiDiXie™-HS has high sensitivity and high specificity in colorectal tumors.YiDiXie™-D has relatively high sensitivity and very high specificity in colorectal tumors. YiDiXie ™ -SS significantly reduced false-positive rates for FOBT, CEA, CA125, and CA19-9 with essentially no increase in delayed treatment for colorectal cancer.YiDiXie™-HS substantially reduced false-negative rates for FOBT, CEA, CA125, and CA19-9. YiDiXie™-D can significantly reduce the false-positive rate of FOBT, CEA, CA125 and CA19-9, or significantly reduce the false-negative rate of FOBT, CEA, CA125 and CA19-9 while maintaining a high level of specificity. YiDiXie ™ tests have an important diagnostic value in colorectal cancer, and are expected to solve the problems of “high false-positive rate” and “high false-negative rate” of FOBT, CEA, CA125 and CA19-9. Clinical trial number ChiCTR2200066840.
Background Breast cancer is a serious threat to women’s health and breast cancer screening is of great importance. Breast ultrasound or mammography is widely used for screening or diagnosis of breast tumors, However, false-positive breast ultrasound or mammogram results can lead to misdiagnosis and wrong puncture biopsy, while false-negative breast ultrasound or mammogram results can lead to missed diagnosis and delayed treatment. There is an urgent need to find a convenient, cost-effective and noninvasive method to reduce the false-positive rate and the false-negative rate of breast ultrasound or mammography. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in breast cancer. Patients and methods 816 subjects (malignant group, n=778; benign tumor group, n=38) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™ tests were evaluated respectively. Results The sensitivity of YiDiXie™-SS was 97.8% (95% CI: 96.5% - 98.6%) and its specificity was 63.2% (95% CI: 47.3% - 76.6%). This means that YiDiXie™-SS has an extremely high sensitivity and relatively high specificity in breast tumors.YiDiXie™-HS has a sensitivity of 84.4% (95% CI: 81.7% - 86.8%) and a specificity of 86.8% (95% CI: 72.7% - 94.2%). This means that YiDiXie™-HS has high sensitivity and specificity in breast tumors.YiDiXie™-HS has a sensitivity of 73.8% (95% CI: 70.6% - 76.7%) and a specificity of 94.7% (95% CI: 82.7% - 99.1%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in breast tumors. The sensitivity of YiDiXie™-SS in ultrasound and mammography-positive patients was 97.8% (95% CI: 96.5% - 98.7%), 97.6% (95% CI: 95.8% - 98.6%), and the specificity was 63.6% (95% CI. 46.6% - 77.8%), 58.3% (95% CI: 32.0% - 80.7%), respectively. This means that the application of YiDiXie™-SS reduced ultrasound and mammography false-positive rates by 63.6% (95% CI: 46.6% - 77.8%) and 58.3% (95% CI: 32.0% - 80.7%), respectively, with essentially no increase in the leakage of malignant tumors. The sensitivity of YiDiXie™-HS in ultrasound and mammography-negative patients was 84.8% (95% CI: 69.1% - 93.9%), 85.7% (95% CI: 76.7% - 91.6%), and the specificity was 60.0% (95% CI. 23.1% - 92.9%), 80.0% (95% CI: 37.6% - 99.0%), respectively. This means that the application of YiDiXie™-HS reduced the false-negative rates of ultrasound and mammography by 84.8% (95% CI: 69.1% - 93.9%), 85.7% (95% CI: 76.7% - 91.6%), respectively. The sensitivity of YiDiXie™-D in ultrasound and mammography-positive patients was 74.0% (95% CI: 70.8% - 77.0%), 76.9% (95% CI: 73.0% - 80.4%), and the specificity was 93.9% (95% CI. 80.4% - 98.9%), 91.7% (95% CI: 64.6% - 99.6%), respectively. This means that YiDiXie™-D reduced the false positive rate of ultrasound and mammography by 93.9% (95% CI: 80.4% - 98.9%), 91.7% (95% CI: 64.6% - 99.6%), respectively. The sensitivity of YiDiXie™ -D in ultrasound and mammography-negative patients was 72.7% (95% CI: 55.8% - 84.9%), 75.0% (95% CI: 64.8% - 83.0%), and its specificity was 100% (95% CI. 56.6% - 100%), 100% (95% CI: 56.6% - 100%), respectively. This means that YiDiXie™-D reduces the false negative rate of ultrasound and mammography by 72.7% (95% CI: 55.8% - 84.9%) and 75.0% (95% CI: 64.8% - 83.0%), respectively, while maintaining a high specificity. Conclusion YiDiXie™-SS has extremely high sensitivity and relatively high specificity in breast tumors.YiDiXie™-HS has high sensitivity and high specificity in breast tumors.YiDiXie™-D has relatively high sensitivity and extremely high specificity in breast tumors.YiDiXie™-SS significantly reduces the rate of false positives by breast ultrasound or mammography with essentially no increase in delayed treatment of breast cancer. YiDiXie™-HS significantly reduces the rate of false negatives on breast ultrasound or mammograms.YiDiXie™-D significantly reduces the rate of false positives on breast ultrasound or mammograms or significantly reduces the rate of false negatives while maintaining a high level of specificity. YiDiXie™ tests has significant diagnostic value in breast cancer and is expected to solve the problems of “high false positive rate” and “high false negative rate” of breast ultrasound or mammography.
Background Thyroid tumor, as an endocrine tumor with increasing incidence, causes a heavy economic burden. Thyroid ultrasound is widely used for screening or diagnosis of thyroid tumors. However, false-positive thyroid ultrasound results can lead to misdiagnosis and wrong puncture biopsy, while false-negative thyroid ultrasound results can lead to missed diagnosis and delayed treatment. There is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-positive and false-negative rates of thyroid ultrasound. The aim of the present study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in thyroid cancer. Patients and methods 843 subjects (malignant group, n=820; benign group, n=23) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie ™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS were evaluated respectively. Results The sensitivity of YiDiXie™-SS was 98.5% (95% CI: 97.5% - 99.2%) and its specificity was 65.2% (95% CI: 44.9% - 81.2%). This means that YiDiXie ™ -SS has an extremely high sensitivity and relatively high specificity in thyroid tumors.YiDiXie™-HS has a sensitivity of 84.3% (95% CI: 81.6% - 86.6%) and a specificity of 87.0% (95% CI: 67.9% - 95.5%). This means that YiDiXie™-HS has high sensitivity and specificity in thyroid tumors.YiDiXie™-D has a sensitivity of 75.5% (95% CI: 72.4% - 78.3%) and a specificity of 95.7% (95% CI: 79.0% - 99.8%). This means that YiDiXie™-D has relatively high sensitivity and very high specificity in thyroid tumors.The sensitivity of YiDiXie™-SS in patients with positive thyroid ultrasound was 98.4% (95% CI: 97.3% - 99.1%) and the specificity was 64.3% (95% CI: 38.8% - 83.7%). This means that the application of YiDiXie ™ -SS reduced the false-positive thyroid ultrasound rate by 64.3% (95% CI: 38.8% - 83.7%) with essentially no increase in malignant tumor underdiagnosis.The sensitivity of YiDiXie™-HS in thyroid ultrasound-negative patients was 90.0% (95% CI: 79.9% - 95.3%) and the specificity 88.9% (95% CI: 56.9%). (95% CI: 56.5% - 99.4%). This means that the application of YiDiXie™-HS reduced the false negative rate of thyroid ultrasound by 90.0% (95% CI: 79.9% - 95.3%).YiDiXie ™-D has a sensitivity of 75.3% (95% CI: 72.1% - 78.2%) and a specificity of 92.9% (95% CI: 68.5% - 99.6%) in patients with positive thyroid ultrasound. This means that YiDiXie™-D reduces the rate of false-positive thyroid ultrasounds by 92.9% (95% CI: 68.5% - 99.6%). YiDiXie™-D has a sensitivity of 78.3% (95% CI: 66.4% - 86.9%) and a specificity of 100% (95% CI: 70.1% - 100%) in patients with negative thyroid ultrasounds. This means that YiDiXie™-D reduces the false-negative rate of thyroid ultrasound by 78.3% (95% CI: 66.4% - 86.9%) while maintaining high specificity. Conclusion YiDiXie™-SS has extremely high sensitivity and relatively high specificity in thyroid tumors.YiDiXie™-HS has high sensitivity and high specificity in thyroid tumors.YiDiXie ™ -D has relatively high sensitivity and extremely high specificity in thyroid tumors. YiDiXie™-SS significantly reduces thyroid ultrasound false-positive rates with essentially no increase in delayed treatment for thyroid cancer.YiDiXie ™ -HS significantly reduces thyroid ultrasound false-negative rates.YiDiXie™-D significantly reduces thyroid ultrasound false-positive rates or significantly reduces its false-negative rates while maintaining high specificity. YiDiXie™ tests have vital diagnostic value in thyroid cancer, and are expected to solve the problems of “high false-positive rate” and “high false-negative rate” of thyroid ultrasound. Clinical trial number ChiCTR2200066840.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
'/%3e%3cuse xlink:href='%23a' transform='rotate(144 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(216 450 300)'/%3e%3cuse xlink:href='%23a' transform='rotate(288 450 300)'/%3e%3c/svg%3e)